Researchers have identified new strategies for developing a vaccine against hepatitis C by studying the immune responses of a…
Articles by Lindsey Shapiro, PhD
Inventiva’s investigational oral therapy lanifibranor safely reduced blood sugar levels and eased signs of liver disease among people with…
The Center for Disease Analysis (CDA) Foundation has granted $2.1 million in funding to 14 U.S. organizations to help…
A possible therapeutic target for fatty liver disease (FLD) has been identified by researchers studying the natural defense mechanisms…
The U.S. Food and Drug Administration (FDA) has approved Rezdiffra (resmetirom) for the treatment of people with noncirrhotic nonalcoholic steatohepatitis…
Up to six years of treatment with Livmarli (maralixibat), which is approved for reducing itch, or pruritus, in…
A global outbreak of severe hepatitis in children just after COVID-19 restrictions were lifted could have been caused by…
Daily treatment with seladelpar, CymaBay Therapeutics’ investigational oral candidate for people with primary biliary cholangitis (PBC), was shown…
Most liver transplant centers in the U.S. continue to use stigmatizing language on their websites that could make people with…
Pliant Therapeutics’ investigational oral treatment bexotegrast safely eases itching and is associated with signs of better liver function and less…